RT Journal Article SR Electronic T1 Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTCs) Relevant to Parenteral Extractables and Leachables (E&Ls) JF PDA Journal of Pharmaceutical Science and Technology JO PDA J Pharm Sci Technol FD Parenteral Drug Association (PDA) SP 369 OP 383 DO 10.5731/pdajpst.2021.012693 VO 76 IS 5 A1 Masuda-Herrera, Melisa J. A1 Bercu, Joel P. A1 Broschard, Thomas H. A1 Burild, Anders A1 Hasselgren, Catrin A1 Parris, Patricia A1 Ford, Lucie C. A1 Graham, Jessica A1 Stanard, Brad A1 Comerford, Michele A1 Lettiere, Daniel A1 Erler, Steffen A1 Callis, Courtney M. A1 Morinello, Eric A1 Muster, Wolfgang A1 Martin, Elizabeth A. A1 Griffin, Troy R. A1 Nagao, Lee A1 Cruz, Maureen YR 2022 UL http://journal.pda.org/content/76/5/369.abstract AB The threshold of toxicological concern (TTC), i.e., the dose of a compound lacking sufficient experimental toxicity data that is unlikely to result in an adverse health effect in humans, is important for evaluating extractables and leachables (E&Ls) as it guides analytical testing and minimizes the use of animal studies. The Extractables and Leachables Safety Information Exchange (ELSIE) consortium, which consists of member companies that span biotechnology, pharmaceutical, and medical device industries, brought together subject matter expert toxicologists to derive TTC values for organic, non-mutagenic E&L substances when administered parenterally. A total of 488 E&L compounds from the ELSIE database were analyzed and parenteral point of departure (PPOD) estimates were derived for 252 compounds. The PPOD estimates were adjusted to extrapolate to subacute, subchronic, and chronic durations of nonclinical exposure and the lower fifth percentiles were calculated. An additional 100-fold adjustment factor to account for nonclinical species and human variability was subsequently applied to derive the parenteral TTC values for E&Ls. The resulting parenteral TTC values are 35, 110, and 180 μg/day for human exposures of >10 years to lifetime, >1-10 years, and ≤1 year, respectively. These parenteral TTCs are expected to be conservative for E&Ls that are considered non-mutagenic per ICH M7(R1) guidelines.